Premium
Additional genetic risk factor for death in children with acute lymphoblastic leukemia: A common polymorphism of the MTHFR gene
Author(s) -
Pietrzyk Jacek J.,
BikMultanowski Miroslaw,
Balwierz Walentyna,
Skoczen Szymon,
Wojcik Dorota,
Chybicka Alicja,
SikorskaFic Barbara,
Matysiak Michal,
Szczepanski Tomasz,
SontaJakimczyk Danuta,
Ploszynska Anna,
Balcerska Anna,
Mycko Katarzyna,
Bodalski Jerzy,
KrawczukRybak Maryna,
Kowalczyk Jerzy,
Koltan Andrzej,
Sobol Grazyna,
Derwich Katarzyna,
Kwinta Przemko
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21815
Subject(s) - medicine , methylenetetrahydrofolate reductase , genotyping , genotype , lymphoblastic leukemia , prospective cohort study , oncology , leukemia , polymorphism (computer science) , acute leukemia , gene , genetics , biology
Background The presence of metabolically important genetic polymorphisms may affect treatment efficacy in patients with malignancies. The objective of this prospective multicenter study was to evaluate the role of selected polymorphisms of genes associated with metabolism of chemotherapeutic drugs as prognostic markers in children with acute lymphoblastic leukemia. Procedure Genotyping for the presence of 7 genetic variants in 403 patients and analysis of death cases were performed. Results Thirty‐one children died before reaching remission maintenance phase. Genetic analysis revealed in this group increased frequency of homozygosity for c.677C>T polymorphism of the MTHFR gene (26% vs. 8% in the survivors; OR 4.09; 95% CI 1.67–10; adjusted for multiple testing P = 0.028). Conclusion Our data suggest that modification of anti‐leukemic treatment should be considered in patients homozygous for c.677C>T polymorphism. Pediatr Blood Cancer 2009;52:364–368. © 2008 Wiley‐Liss, Inc.